Table 2.
Parameter estimates (95% confidence intervals) for average HbA1c (mmol/mol) levels over the follow-up
| Baseline level at 01/2014 | Pre-policy change trend in 01/2014–12/2016 | Change in level at the time of the policy change in 01/2017 | Post-policy change trend in 02/2017–9/2019 | |
|---|---|---|---|---|
| All patients (n = 8143) | 52.40 (51.88 to 52.91) | 0.07 (0.04 to 0.09) | 0.81 (0.04 to 1.58) | 0.03 (− 0.03 to 0.08) |
| Subgroup analyses: | ||||
| Patients aged < 75 years (n = 5203) | 52.05 (51.50 to 52.60) | 0.06 (0.04 to 0.09) | 0.79 (− 0.04 to 1.62) | 0.04 (− 0.02 to 0.10) |
| Patients aged ≥75 years (n = 2940) | 53.39 (52.59 to 54.19) | 0.06 (0.02 to 0.10) | 1.53 (0.40 to 2.66) | 0.00 (−0.08 to 0.09) |
| ≤ 10 years duration of T2D (n = 4243) | 47.35 (46.80 to 47.90) | 0.06 (0.04 to 0.09) | 0.68 (−0.03 to 1.39) | 0.05 (− 0.01 to 0.11) |
| > 10–15 years duration of T2D (n = 1976) | 53.15 (52.41 to 53.89) | 0.09 (0.06 to 0.13) | 0.85 (−0.29 to 1.99) | 0.02 (− 0.06 to 0.09) |
| > 15 years duration of T2D (n = 1924) | 59.76 (58.57 to 60.95) | 0.03 (−0.02 to 0.09) | 1.49 (− 0.11 to 3.09) | 0.02 (− 0.11 to 0.15) |
| Used only metformin in 2016 (n = 2271) | 42.79 (42.44 to 43.14) | 0.06 (0.04 to 0.07) | 1.28 (0.83 to 1.73) | 0.05 (0.02 to 0.09) |
| Used metformin and other OAD in 2016 (n = 1430) | 49.85 (49.17 to 50.53) | 0.09 (0.06 to 0.12) | 0.92 (−0.10 to 1.94) | 0.06 (−0.01 to 0.13) |
| Used only other diabetes medications than insulin or metformin in 2016 (n = 726) | 46.71 (45.99 to 47.43) | 0.04 (0.01 to 0.08) | 3.56 (2.50 to 4.62) | 0.02 (−0.06 to 0.10) |
| Used insulin and OAD (incl. metformin) in 2016 (n = 2112) | 61.78 (60.88 to 62.68) | 0.06 (0.02 to 0.10) | 0.92 (−0.39 to 2.22) | −0.03 (− 0.12 to 0.07) |
| Used only insulin in 2016 (n = 577) | 62.18 (60.98 to 63.38) | −0.00 (− 0.06 to 0.05) | 0.42 (−1.28 to 2.12) | 0.07 (− 0.06 to 0.20) |
Abbreviations: OAD oral antidiabetic drug;, T2D type 2 diabetes